You keep hearing about GLP-1, but what is GLP-1, really? It shows up in the news, in ads, and in conversations with friends who started a new medicine. Nobody stops to explain what the term actually means.
So you are left guessing. Is GLP-1 a drug, a hormone, or a brand name? Is it something your body already makes, or something you have to take?
This guide answers that in plain language. You will learn what GLP-1 is, how it works in your body, what GLP-1 medicines do, who they help, and what to know about safety.
KEY TAKEAWAYS
- GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat.
- It helps release insulin, lowers glucagon, slows digestion, and reduces appetite.
- GLP-1 medicines copy the hormone but resist quick breakdown, so one dose lasts about a week.
- Wegovy® and Zepbound® are approved for chronic weight management in adults who meet BMI criteria.
- GLP-1 medicine labels, including Wegovy® and Zepbound®, carry a boxed warning about thyroid tumors seen in animal studies.
What readers want to figure out
- You want a plain answer to what GLP-1 actually is.
- You want to know what GLP-1 medicines do inside your body.
- You want to know who GLP-1 medicines are approved to help.
- You want a realistic sense of side effects and safety.
- You want to know how GLP-1 relates to brand names like Wegovy® and Zepbound®.
What GLP-1 actually means
GLP-1 stands for glucagon-like peptide-1. It is a hormone that specialized cells in your gut, called L-cells, release after you eat.
GLP-1 belongs to a group of hormones called incretins. Incretins help your body manage blood sugar right after a meal.
Native GLP-1 does not stick around for long. An enzyme called DPP-4 breaks it down in about one to two minutes, so your gut keeps releasing more each time you eat.
GLP-1 itself is a peptide, a short chain of amino acids. It has 30 or 31 amino acids, cut from a longer parent protein called proglucagon.
How GLP-1 works in your body
GLP-1 attaches to a matching receptor and triggers four actions at once. Together, they help steady your blood sugar and turn down hunger.
1. It tells the pancreas to release more insulin, but only when blood sugar is high.
2. It tells the pancreas to release less glucagon, the hormone that raises blood sugar.
3. It slows how fast food leaves your stomach, so fullness lasts longer.
4. It quiets appetite signals in the brain’s hypothalamus, so hunger cues turn down.
These four actions are why GLP-1 plays a role in both blood sugar and appetite. GLP-1 medicines are built to trigger the same four actions, just for longer.
GLP-1 is not a foreign substance. It is a hormone your body already makes every time you eat.
Why GLP-1 medicines exist
Native GLP-1 is powerful, but it fades fast. Researchers found a way to build molecules that act like GLP-1 while resisting the enzyme that normally breaks it down within minutes.
These lab-made versions are called GLP-1 receptor agonists. A single weekly dose can keep signaling your body for about a week instead of a couple of minutes.
Several GLP-1 receptor agonist medicines are approved in the United States, such as Wegovy® and Zepbound®. Each one carries its own approved use, dosing schedule, and safety information.
A once-weekly injection means fewer decisions during a busy week. Some GLP-1 medicines also come as a daily pill instead, depending on the brand.
Who GLP-1 medicines help
GLP-1 receptor agonist medicines fall into two broad groups, based on their approved use. Some are approved for chronic weight management, and some are approved for type 2 diabetes.
Wegovy® and Zepbound® are approved for chronic weight management in adults with a body mass index of 30 or higher. The threshold drops to 27 or higher when a weight-related condition is also present, such as high blood pressure or type 2 diabetes.
Ozempic® and Mounjaro® use the same active ingredients as Wegovy® and Zepbound®, but they are approved for type 2 diabetes instead. They help adults manage blood sugar alongside diet and exercise.
Weight and blood sugar are closely linked for many people, which is part of why this medicine class covers both approved uses. A doctor can help sort out which use, if any, applies to you.
How well do GLP-1 medicines work?
Clinical trial results give the clearest picture. Results are usually reported as the average percent of body weight lost over a set number of weeks.
The table below shows results from the two major trials behind Wegovy® and Zepbound®: STEP 1, with 1,961 adults, and SURMOUNT-1, with 2,539 adults.
| GLP-1 medicine (brand) | Approved use | Named trial (sample size) | Reported average weight loss |
|---|---|---|---|
| Wegovy® (semaglutide) | Chronic weight management: BMI 30+, or 27+ with a weight-related condition | STEP 1 (1,961 adults) | 14.9% of body weight at 68 weeks, vs. 2.4% with placebo |
| Zepbound® (tirzepatide) | Chronic weight management: BMI 30+, or 27+ with a weight-related condition | SURMOUNT-1 (2,539 adults) | Up to 22.5% of body weight at 72 weeks, highest dose, vs. 2.4% with placebo |
Figures reflect the FDA-approved brand-name products studied in each named trial. Individual results vary.
Averages describe a group, not one person. Some people lose more than the average, and some lose less, depending on starting weight, dose, and how long they stay on treatment.
Averages are not promises. Individual results vary from person to person and medicine to medicine.
Is GLP-1 the same as Ozempic® or Wegovy®?
GLP-1 is the hormone. Ozempic® is one specific brand-name medicine built to copy it.
Ozempic® and Wegovy® both contain semaglutide, and Rybelsus® is a pill version of the same active ingredient. Mounjaro® and Zepbound® both contain tirzepatide instead, which also acts on a second hormone receptor called GIP.
Calling every GLP-1 medicine Ozempic® is a common shortcut, but it is not accurate. Each brand name points to a specific active ingredient, dose range, and approved use.
Side effects: what to expect
Most side effects from GLP-1 medicines involve the gut. They tend to show up early, especially while the dose is still increasing.
Common and usually short-lived
The most reported side effects are nausea, vomiting, diarrhea, and constipation. They often ease as the body adjusts, and a slower dose increase can help.
Most GLP-1 medicines start at a low dose and increase slowly over several weeks. Doctors often use this step-by-step approach, along with smaller, protein-forward meals, to help the stomach adjust.
Less common but more serious
Pancreatitis and gallbladder problems show up at low rates in studies and safety reports. Ongoing nausea or vomiting can also lead to dehydration, which can stress the kidneys.
The thyroid boxed warning, explained
Wegovy®, Zepbound®, and other medicines built from semaglutide or tirzepatide carry an FDA boxed warning, the strongest warning label a medicine can carry. It concerns a rare thyroid tumor called medullary thyroid carcinoma.
The warning is based on studies in rodents, where these medicines caused thyroid C-cell tumors. It is not known whether this risk applies to humans.
Because of this, these medicines are not recommended for people with a personal or family history of medullary thyroid carcinoma. The same caution applies to a condition called Multiple Endocrine Neoplasia syndrome type 2.
Who should be careful with GLP-1 medicines
GLP-1 medicines are not right for everyone. Pregnancy, a personal or family history of thyroid cancer, and a history of pancreatitis are all reasons a doctor may advise against them.
A doctor or nurse practitioner can review your health history and help you weigh whether a GLP-1 medicine fits your situation. This conversation matters more than any single number on a label.
Can you support GLP-1 naturally?
Some research suggests that certain habits can nudge your body’s own GLP-1 release upward. High-fiber meals, protein at each meal, and regular movement are commonly mentioned examples.
The effect is real, but modest, since native GLP-1 only lasts a couple of minutes either way. Lifestyle habits can support a treatment plan, but they are not the same as a prescribed GLP-1 medicine.
The takeaway
GLP-1 is a hormone your gut already makes every time you eat. GLP-1 medicines copy that hormone and help it last longer, which is why they can support blood sugar and appetite. Wegovy® and Zepbound® show meaningful average results in named trials, and every medicine in this class carries a boxed warning worth understanding before you start.
FREQUENTLY ASKED QUESTIONS
No, GLP-1 is the hormone your body makes, and Ozempic® is one specific brand-name medicine built to copy it. Ozempic® and Wegovy® both contain semaglutide, while Mounjaro® and Zepbound® contain a different active ingredient called tirzepatide. Calling every GLP-1 medicine Ozempic® is a common shortcut, but it is not accurate, since each brand carries its own approved use and dosing.
GLP-1 stands for glucagon-like peptide-1. It is a hormone that L-cells in your gut release after a meal, and it belongs to a group of hormones called incretins. Incretins help your body manage blood sugar right after you eat. GLP-1 medicines are lab-made versions built to copy this hormone and resist the enzyme that normally breaks it down within minutes.
The GLP-1 your body makes on its own is a normal, safe part of digestion. GLP-1 medicines have years of safety data and clear FDA-approved uses, though nausea and other side effects can happen. Medicines like Wegovy® and Zepbound® also carry a boxed warning about thyroid tumors seen in rodent studies. The safest path is to use an approved medicine and let a doctor guide the decision.
GLP-1 and insulin are both hormones, but they do different jobs. GLP-1 is released by your gut after a meal and tells the pancreas to release insulin when blood sugar is high. Insulin is released by the pancreas and directly moves sugar out of the blood and into your cells. In short, GLP-1 helps trigger the release of insulin, but it is not insulin itself.
The most common side effects are gut-related, including nausea, vomiting, diarrhea, and constipation, especially while the dose is increasing. Less often, GLP-1 medicines are linked to pancreatitis, gallbladder problems, or dehydration that can stress the kidneys. Medicines in this class, including Wegovy® and Zepbound®, also carry a boxed warning about thyroid tumors seen in rodent studies. A prescriber can help you weigh these risks.
Diet and lifestyle can nudge your body’s own GLP-1 release upward. High-fiber meals, protein at each meal, and regular movement are commonly mentioned examples in early research. The effect is real but modest, since native GLP-1 only lasts a couple of minutes before it breaks down. Lifestyle habits can support a plan, but they are not a substitute for a prescribed GLP-1 medicine.
Wegovy® and Zepbound® are approved for adults with a body mass index of 30 or higher. The threshold drops to 27 or higher with a weight-related condition, such as high blood pressure or type 2 diabetes. Ozempic® and Mounjaro® are approved for adults with type 2 diabetes instead, to help manage blood sugar alongside diet and exercise.
No. Clinical trials report averages, and individual results vary widely around that average. In the STEP 1 trial of 1,961 adults, people on Wegovy® lost an average of 14.9% of body weight. In the SURMOUNT-1 trial of 2,539 adults, people on the highest dose of Zepbound® lost up to 22.5%. Starting weight, dose, and treatment length all affect the outcome.
Go deeper
Wegovy® vs. Zepbound®, compared
Now that you know what GLP-1 is, here is the simple, side-by-side look at the two leading weight-management brands.
→ See Wegovy® vs Zepbound®
SOURCES
3. ClinicalTrials.gov. STEP 1 study record (NCT03548935). US National Library of Medicine.
4. ClinicalTrials.gov. SURMOUNT-1 study record (NCT04184622). US National Library of Medicine.
5. US Food and Drug Administration. WEGOVY (semaglutide) injection, prescribing information. 2021.
Last updated: 2026-08-14 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
Comments